DGAP-News: InflaRx raises EUR 31 million (US$ 34M) in a

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 21, 2016 at 1:15 PM

DGAP-News: InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development

DGAP-News: InflaRx GmbH / Key word(s): Financing InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development 21.07.2016 / 18:45 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- InflaRx raises EUR 31 million (US$ 34M) in a Series C financing round to foster complement inhibitor development Jena, Germany, July 21, 2016 - InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today that it has raised EUR 31 million (USD 34 million) in a Series C round. The financing was composed of new investors such as Staidson Hongkong Investment Company ltd. ("STS"), international industrial investors and family offices as well as existing investors. Proceeds from the round will be used to advance clinical phase II development of the lead drug candidate IFX-1, a first-in-class monoclonal anti-complement C5a antibody, in various acute and chronic inflammatory indications as well as the preclinical development of the follow-up pipeline-molecules. "InflaRx has made significant progress in the field of terminal complement C5a inhibition, putting us in a lead position, globally. In January, we validated IFX-1 in a Phase IIa clinical trial that provided excellent data. This has been well accepted by our existing and new shareholders," said Prof. Dr. Niels Riedemann, founder and CEO of InflaRx. "We will use the proceeds of this Series C financing to develop our lead drug candidate IFX-1 in different inflammatory disease indications with high unmet medical need and orphan drug potential," he added. In January 2016, InflaRx successfully completed its first clinical Phase IIa trial in patients suffering from early septic organ dysfunction; all primary clinical endpoints were met. In June 2016, the company initiated its second phase II trial of IFX-1 in patients undergoing complex cardiac surgery. "We have established long standing research collaborations with internationally recognized research groups in China and thus have built a strong network in the region. This has helped us to attract STS as a major new investor in our unique technology", Prof. Renfeng Guo, founder and CSO of InflaRx stated. "Despite the very challenging market conditions, we have been able to bring together an international syndicate of investors and family offices that believe in the tremendous potential of our technologies. The proceeds of this financing will enable us to reach multiple significant value inflection points and generate a variety of strategic options," commented Arnd Christ, CFO of InflaRx. About IFX-1: IFX-1 is a first-in-class monoclonal anti-complement C5a antibody which offers a complete biological blocking activity and selectivity towards its target, C5a. Thus, IFX-1 leaves the important formation of the membrane attack complex (C5b-9) intact while being capable of blocking C5a mediated effects in humans instantly and completely. IFX-1 controls the inflammatory response-driven tissue and organ damage by specifically blocking C5a as a key "amplifier" of this response in preclinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development and has thus far successfully completed a clinical phase IIa study in patients suffering from septic organ dysfunctions in which all primary endpoints were met. IFX-1 is currently being developed in several different clinical indications. About InflaRx: InflaRx is a biopharmaceutical company focusing on the development of new breakthrough therapeutics controlling inflammation resulting from terminal complement activation. Its lead drug, IFX-1, is a first-in-class complement C5a inhibiting monoclonal antibody, which the company believes holds vast potential as a game changer in inflammation. The Company also is developing additional molecules, IFX-2 and IFX-3, targeting chronic inflammation related diseases. InflaRx was founded in 2007 and is headquartered in Jena, Germany. The team consists of internationally renowned experts in complement and clinical research. InflaRx is financed by Staidson Hongkong Investment Company ltd, bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international industrial and private investors. Contacts: InflaRx GmbH Niels C. Riedemann - CEO Arnd Christ - CFO Email: info[at]inflarx.de Tel: +49-3641-508180 www.inflarx.de MC Services AG Katja Arnold / Dr. Cora Kaiser / Shaun Brown Email: inflarx[at]mc-services.eu Tel: +49-89-210 2280 The Trout Group Jennifer Porcelli / Thomas Hoffmann Email: JPorcelli[at]troutgroup.com / thoffmann[at]troutgroup.com Tel: +1 646 378 2900 --------------------------------------------------------------------------- 21.07.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- 484973 21.07.2016

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Porte Brown Hits #3 for Young Accountants in 2026

Fresh Faces Rank Porte Brown High Now here's a thing most big-name firms might envy—Porte Brown nabbed the #3 spot on Accounting Today's 2026 list of Best Firms for Young Accountants. This isn't some fly-by-night recognition; it speaks to their whole gig—nurturing, training, and growing young talent in the world of numbers. When you talk about setting the bar for...

Bit Digital Shifts Focus: Q3 2026 Sees Strategic Moves

Bit Digital's Strategic Shakeup Ah, the digital gold rush is heating up again. Bit Digital, the outfit focused on Ethereum strategies and AI, dropped their financial results for Q3 2026. Picture a company at a strategic crossroads, shedding bitcoin mining baggage to grab hold of fresh opportunities in Ethereum staking and AI infrastructure. Bit Digital's earnings paint a...

Lululemon Lawsuit Looms: Investors Face Key Decisions

Seems Lululemon just tripped on its yoga mat. When a company like Lululemon Athletica, Inc (NASDAQ:LULU) sees a 17.38% slide in stock, every savvy investor knows there's more beneath the surface. Squarely in the crosshairs of a securities fraud class action, the brand synonymous with upscale athleisure faces harsh scrutiny. And the deadline's ticking—even the suits know...

Dexter Bowling BVL Event Series Honors Veterans

A Humble Roll to Honor Service Now, here's a heartwarming tale to chew over your morning coffee: Dexter Bowling is teaming up with the Bowlers to Veterans Link (BVL) for some feel-good festivities this holiday season. Beginning December, four special bowling events are rolling out across the U.S., designed just for veterans to connect over the camaraderie of spare strikes...

HSG Laser Boosts EU Presence with Düsseldorf Showroom

HSG Laser Makes a Bold Move in Europe When you're ripping off the band-aid and just diving into the hard truth, it's no small potatoes that HSG Laser has kicked open the doors to a shiny new showroom in Düsseldorf, Germany. This ain't just another brick in the wall—it's a sprawling 2,000 m² facility that marks a 20-year track record of tackling the European sector...

Kargo's Tech Boosts Profit on Seafood Supply Chain

Revolutionizing Seafood Logistics with Kargo You'd think managing seafood shipments would be a simpler gig than charting ocean routes, but think again. Northern Wind, a major player in seafood processing, just proved the power of tech in an old-school business by partnering with a slick AI outfit called Kargo. Their facility in New Bedford, Massachusetts now magically...

tZERO Gains CFTC Approval, Paves Derivatives Path

Breaking into New Territory: tZERO's CFTC Triumph tZERO just scored a touchdown in the financial arena with its newly minted approval from the Commodity Futures Trading Commission. This green light allows them to dive into derivatives trading and clearing, a colossal leap for their Infrastructure-as-a-Service model. You could almost feel the corporate chest-thumping as...

Global Youth Co-Creation Plan Inspires Deep Living

Rediscovering Authenticity in a Fast-Paced World In a world obsessed with snappy content and instant fame, it's refreshing to see an initiative like the Global Youth Image Co-creation Plan take center stage. Unveiled at the third Hong Kong Night, the plan isn't just another flash in the pan. No, it's a call—practically a rallying cry—for young creators worldwide to...

Oman's Hydrogen Expansion: New Projects, Big Ambitions

Oman's Green Hydrogen Strategy Takes Bold Steps Say what you will about Oman, they fancy themselves as the green hydrogen pioneers of the future. Here’s the kicker: they’ve just awarded two heavy-hitting green hydrogen projects in Duqm, and they’re not stopping there. Announced at COP31, this is their third auction’s pièce de résistance, asserting Oman’s green...

M-tron Industries Delivers Robust Q3 2026 Performance

Key Takeaways from M-tron's Q3 Results Well, M-tron Industries just put out numbers for Q3 2026 that’ve got the street buzzing. With 11.1% growth in revenues, their top-line performance ain't something to sniff at, especially when the defense and aerospace sectors drive the engine. They're not just coasting on momentum—there's some solid guidance here, with a backlog...